Plain-English translation of NCT05954910 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a real-world study that will follow up to 1,000 Chinese adults with diffuse large B-cell lymphoma (a type of blood cancer) who are receiving polatuzumab, a targeted antibody medication. Researchers want to understand how well this treatment works and how safe it is when used in regular medical practice, rather than in a controlled trial setting.
While this medication has been tested in clinical trials, doctors need to understand how it performs in real-world situations with diverse patients who may be older, frailer, or have other health conditions. This study will help doctors learn whether the medication is as effective and safe for everyday patients in China.
You likely qualify if…
You likely don't qualify if…
You would not receive the medication as part of the study — you'd be receiving it through your regular doctor anyway. Instead, researchers would follow your progress with regular check-ins and assessments over approximately three years to track how you respond to the treatment and any side effects you experience. You can withdraw at any time, and the study would end if your condition improves, worsens significantly, or at the end of the three-year period.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China